Inhibrx Biosciences (INBX) Stock Price & Analysis
Score
AI Analysis
SnapshotInhibrx Biosciences is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 69/100) in Biotechnology. Under the hood: revenue compounding ~148% annually over recent years. Street targets still imply ~242% upside.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Inhibrx Biosciences Inc. (INBX) last printed $83.30. Equity value is $1.23B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| $6.67M | $8.39M | $8.6M | $9.09M | $12.81M | $7.12M | $2.19M | $1.8M | $200,000.00 | $1.3M |
About
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.